TRACON Pharmaceuticals, Inc.
TCON · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $55 | $100 | $3,045 | $0 |
| % Growth | -45% | -96.7% | – | – |
| Cost of Goods Sold | $0 | $4 | $3 | $4 |
| Gross Profit | $55 | $96 | $3,042 | -$4 |
| % Margin | 100% | 96% | 99.9% | – |
| R&D Expenses | $1,350 | $1,874 | $1,491 | $2,326 |
| G&A Expenses | $1,617 | $1,434 | $1,144 | $1,262 |
| SG&A Expenses | $1,617 | $1,434 | $1,144 | $1,262 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$9 | -$5 | $0 |
| Operating Expenses | $2,967 | $3,308 | $2,635 | $3,588 |
| Operating Income | -$2,912 | -$3,212 | $407 | -$1,588 |
| % Margin | -5,294.5% | -3,212% | 13.4% | – |
| Other Income/Exp. Net | $73 | $44 | $32 | $12,351 |
| Pre-Tax Income | -$2,839 | -$3,168 | $439 | $10,763 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,839 | -$3,168 | $439 | $10,763 |
| % Margin | -5,161.8% | -3,168% | 14.4% | – |
| EPS | -0.94 | -1.33 | 0.22 | 5.85 |
| % Growth | 29.3% | -704.5% | -96.2% | – |
| EPS Diluted | -0.94 | -1.33 | 0.18 | 5.8 |
| Weighted Avg Shares Out | 3,008 | 2,382 | 2,465 | 1,856 |
| Weighted Avg Shares Out Dil | 3,008 | 2,390 | 2,010 | 1,843 |
| Supplemental Information | – | – | – | – |
| Interest Income | $75 | $53 | $37 | $0 |
| Interest Expense | $0 | $0 | $0 | $646 |
| Depreciation & Amortization | $4 | $4 | $3 | $4 |
| EBITDA | -$2,908 | -$3,208 | $405 | $11,417 |
| % Margin | -5,287.3% | -3,208% | 13.3% | – |